{"id":101981,"date":"2026-07-23T23:15:36","date_gmt":"2026-07-23T17:45:36","guid":{"rendered":"https:\/\/premom.in\/?post_type=premom_news&p=101981"},"modified":"2026-07-24T17:27:10","modified_gmt":"2026-07-24T11:57:10","slug":"endometriosis-news-2026-non-hormonal-treatment","status":"publish","type":"premom_news","link":"https:\/\/premom.in\/te\/news\/endometriosis-news-2026-non-hormonal-treatment\/","title":{"rendered":"Endometriosis News 2026: Could a Non-Hormonal Injection Let Indian Women Treat Endometriosis Without Pausing Fertility?"},"content":{"rendered":"

An investigational, non-hormonal peptide injection could offer women a way to treat \u0c0e\u0c02\u0c21\u0c4b\u0c2e\u0c46\u0c1f\u0c4d\u0c30\u0c3f\u0c2f\u0c4b\u0c38\u0c3f\u0c38\u0c4d<\/strong> without shutting down their natural ovulation cycles, a potential turning point for the millions of Indian women who face a difficult trade-off between managing symptoms and trying to conceive. The therapy, called ENDO-205<\/strong>, is being developed by US-based biotech firm EndoCyclic Therapeutics and is currently in clinical development.<\/p>\n\n\n\n

The latest endometriosis news<\/strong> from 2026 centres on ENDO-205<\/strong>, a first-in-class non-hormonal peptide therapy from EndoCyclic Therapeutics. Unlike standard endometriosis medications such as GnRH agonists and oral contraceptives, which work by suppressing estrogen and pausing ovulation, ENDO-205 is designed to target and clear diseased lesion tissue directly. This means women could potentially continue tracking their LH surges and trying to conceive during treatment. ENDO-205 remains investigational and is not yet commercially available in India or elsewhere (EndoCyclic Therapeutics, 2026; NIH SEED, 2024).<\/p>\n\n\n\n

What Is the Latest Endometriosis News in 2026?<\/strong><\/h2>\n\n\n
\n
\"Endometriosis\"<\/figure>\n<\/div>\n\n\n

<\/p>\n\n\n\n

The most closely watched story in \u0c0e\u0c02\u0c21\u0c4b\u0c2e\u0c46\u0c1f\u0c4d\u0c30\u0c3f\u0c2f\u0c4b\u0c38\u0c3f\u0c38\u0c4d<\/strong> research this year is the emergence of disease-modifying, non-hormonal therapies. ENDO-205<\/strong>, an investigational agent from EndoCyclic Therapeutics, has drawn attention because of how it approaches the condition.<\/p>\n\n\n\n

Endometriosis is a chronic condition in which tissue similar to the uterine lining grows outside the uterus, causing chronic pelvic pain, heavy periods, and, for many women, difficulty conceiving. According to the World Health Organization, endometriosis affects an estimated 10% of women of reproductive age globally, translating to a significant burden in India, where diagnostic delays average 7\u201310 years from the onset of symptoms.<\/p>\n\n\n\n

Most endometriosis treatments<\/strong> available today rely on hormonal suppression. Medications like GnRH agonists and combined oral contraceptives control pain by lowering estrogen and pausing ovulation, essentially inducing a temporary medical menopause. For a woman trying to conceive, this creates a bind: treat the pain and pause fertility, or preserve fertility and live with the symptoms.<\/p>\n\n\n\n

ENDO-205 is designed to change that equation. According to EndoCyclic Therapeutics\u2019 pipeline disclosures, the therapy uses a proprietary peptide platform engineered to be selectively absorbed by diseased endometrial tissue outside the uterus. Once inside the lesions, it aims to activate the body\u2019s natural clearance mechanisms, targeting the abnormal tissue directly rather than suppressing hormones throughout the body.<\/p>\n\n\n\n

Why a Non-Hormonal Endometriosis Treatment Matters for Indian Women<\/strong><\/h2>\n\n\n\n

For the Indian women who use fertility tracking tools, including the Premom app, to map their LH surges, basal body temperature (BBT), and cycle patterns, the significance of a non-hormonal<\/em> therapy is substantial.<\/p>\n\n\n\n

Standard endometriosis medication<\/strong> such as GnRH agonists flattens the natural hormonal peaks that make ovulation trackers, ovulation predictor kits (OPKs), and BBT charts meaningful. During treatment, LH surges do not occur, ovulation is halted, and active conception isn\u2019t possible. Women are asked to pause their fertility journey, sometimes for months or years, to manage the condition.<\/p>\n\n\n\n

ENDO-205 is designed to work without triggering this pause. Because it targets only the diseased tissue and doesn\u2019t suppress estrogen or progesterone, the natural menstrual cycle is intended to continue during treatment. If clinical trials confirm this preservation of ovarian function, it would allow women to seek relief from endometriosis pain<\/strong> and lesion burden while simultaneously trying to conceive, a scenario current therapies cannot offer.<\/p>\n\n\n\n

For Indian women dealing with the additional weight of long diagnostic delays and limited access to advanced fertility care outside metro cities, that dual capability could be meaningful.<\/p>\n\n\n\n

ENDO-205 vs. Current Endometriosis Treatments<\/strong><\/h2>\n\n\n
\n
\"ENDO-205<\/figure>\n<\/div>\n\n\n

Source: EndoCyclic Therapeutics pipeline disclosures, 2026.<\/em><\/p>\n\n\n\n

Beyond Endometriosis: Fibroids and Adenomyosis<\/strong><\/h2>\n\n\n
\n
\"Endometriosis<\/figure>\n<\/div>\n\n\n

<\/p>\n\n\n\n

The same peptide platform behind ENDO-205 is being explored for other conditions that affect fertility in Indian women, including uterine fibroids<\/strong> \u0c2e\u0c30\u0c3f\u0c2f\u0c41 adenomyosis<\/strong>.<\/p>\n\n\n\n

Uterine fibroids are non-cancerous muscular growths in the uterine wall that can distort the uterine cavity, cause heavy menstrual bleeding, contribute to implantation failure, and increase the risk of early miscarriage. Adenomyosis is a condition in which uterine lining tissue grows into the muscular wall of the uterus, causing severe cramping and fertility challenges. Both conditions are currently managed with limited options, often involving invasive surgery like myomectomy or hysterectomy in severe cases.<\/p>\n\n\n\n

According to EndoCyclic Therapeutics, the tissue-targeting peptide platform is being adapted to identify and act on fibroid and adenomyosis tissue selectively. If successful, it could open a non-surgical pathway that preserves uterine health for future pregnancies.<\/p>\n\n\n\n

FemLUNA: A Diagnostic Tool Also in Development<\/strong><\/h2>\n\n\n\n

Alongside ENDO-205, EndoCyclic Therapeutics is developing an investigational imaging diagnostic called FemLUNA<\/strong>. Because a definitive endometriosis diagnosis often still requires laparoscopic surgery, the 7\u201310 year diagnostic delay remains one of the biggest problems facing women with the condition, particularly in India, where access to specialist care is uneven.<\/p>\n\n\n\n

FemLUNA is being engineered to visualise endometriosis lesions, including superficial and sub-millimetre lesions that standard ultrasounds and MRIs typically miss, without radiation, heavy metals, or hormonal preparation. Paired with a targeted therapeutic like ENDO-205, the intention is to identify and treat the condition earlier, before it causes lasting damage to pelvic health or fertility.<\/p>\n\n\n\n

What Should Women in India Do Right Now?<\/strong><\/h2>\n\n\n\n

It is important to note that both ENDO-205 and FemLUNA are investigational agents. They must complete clinical trial phases and receive regulatory approval before becoming available. There is no current timeline for availability in India.<\/p>\n\n\n\n

For Indian women managing endometriosis today:<\/p>\n\n\n\n